Abstract 1042P
Background
Stratum C of the INSIGHT platform trial evaluates eftilagimod alpha (efti) combined with standard of care (SOC) 1st line chemo-immunotherapy (IC) in metastatic NSCLC patients (pts). Efti is an MHC class II agonist (soluble LAG-3 protein) activating antigen-presenting cells followed by T-cell (CD4/CD8) activation. Efti aims to enhance efficacy of IC.
Methods
Pts with 1st line advanced or metastatic NSCLC adenocarcinomas (non-squamous) receive carboplatin AUC5 / pemetrexed 500 mg/m2 q3w 4 cycles followed by optional pemetrexed 500 mg/m2 q3w maintenance plus pembrolizumab 200 mg q3w combined with s.c. efti (30 mg) (q2w for 24 weeks; thereafter q3w till week 52). Imaging: q8w. Primary endpoint: feasibility (safety / tolerability). Secondary endpoints include ORR (RECIST 1.1.), PFS, OS.
Results
From 02Aug2021 till data cut off 18Apr2023 21 pts were enrolled and received treatment (median age: 65 years; 66.7% male). No occurrence of unacceptable toxicities. 10 SAE (grade 1-2: 3; grade 3: 4; grade 4: 0; grade 5: 3) were reported. 1 pancreatitis was possibly related to efti (or immunotherapy in general) and unexpected. So far, 4 pts completed max. treatment with efti for 52 weeks. The most frequent AEs were anemia in 18 pts (52.4%, grade 1-2 and 33.3%, grade 3), neutropenia in 18 pts (19.0%, grade 2 and 66.7%, grade 3-4), leukopenia in 16 pts (28.6%, grade 1-2 and 47.6%, grade 3-4) and thrombocytopenia in 14 pts (42.9%, grade 1-2 and 23.8%, grade 3-4). 5 AEs with grade 3 and no AE with grade 4 and 5 were considered related to efti. Out of 21 pts, 14 pts (67%) showed partial response, 5 (24%) stable disease, 2 (9%) progressive disease as BOR. Even pts with negative or low PD-L1 status (TPS) showed promising efficacy signals. Median follow up: 8.3 months, median OS: not reached.
Conclusions
To date, 30 mg efti combined with SOC appears to be feasible and safe with promising signals of efficacy, so that the trial was amended for inclusion of further 30 pts.
Clinical trial identification
EudraCT 2016-002309-20, NCT03252938.
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Steinbacher Hohl 2-26, D-60488 Frankfurt, Germany.
Funding
Immutep GmbH.
Disclosure
S. Al-Batran: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, MacroGenics, Immutep, MSD Sharp & Dohme; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Lilly, AIO Studien gGmbH, MCI Deutschland GmbH; Financial Interests, Personal, Other, CEO/founder: Institute of Clinical Cancer Research IKF at Northwest Hospital; Financial Interests, Institutional, Research Grant: Sanofi, Roche, Celgene, Vifor, Medac, Hospira, Lilly, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, MSD Sharp & Dohme, AstraZeneca, German Cancer Aid (Krebshilfe), German Research Foundation, Federal Ministry of Education and Research. T.O. Goetze: Financial Interests, Personal, Advisory Role: Lilly, MSD Oncology, Bayer, SERVIER, Roche, Novartis, Incyte, Foundation Medicine, Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Research Funding: Deutsche Forschungsgemeinschaft, Gemeinsamer Bundesausschuss; Financial Interests, Institutional, Research Funding: Deutsche Krebshilfe, Lilly, AstraZeneca, Incyte. All other authors have declared no conflicts of interest.
Resources from the same session
1037P - Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors
Presenter: Nicolas Mach
Session: Poster session 19
1039P - First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Presenter: Geoffrey Ku
Session: Poster session 19
1040P - Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours
Presenter: Yasutoshi Kuboki
Session: Poster session 19
1041P - Phase I open-label, dose escalation and expansion study of YH003, an anti-CD40 agonist monoclonal antibody in combination with toripalimab in patients (pts) with advanced solid tumours
Presenter: Ben Markman
Session: Poster session 19
1043P - First-in-human study of TU2218, TGFβRI and VEGFR2 dual inhibitor in patients with advanced solid tumors
Presenter: Do-Youn Oh
Session: Poster session 19
1044P - A phase Ia first-in-human study of JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
Presenter: Jun Zhang
Session: Poster session 19
1045P - Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor
Presenter: Ravit Geva
Session: Poster session 19
1046P - Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results
Presenter: Jung Yong Hong
Session: Poster session 19
1047P - AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Presenter: Ben Tran
Session: Poster session 19